Humacyte, Inc. (NASDAQ:HUMA) Holdings Trimmed by Jump Financial LLC

Jump Financial LLC lessened its stake in shares of Humacyte, Inc. (NASDAQ:HUMA - Free Report) by 71.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 93,763 shares of the company's stock after selling 233,859 shares during the quarter. Jump Financial LLC owned 0.07% of Humacyte worth $474,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the business. Vanguard Group Inc. lifted its stake in shares of Humacyte by 10.8% in the fourth quarter. Vanguard Group Inc. now owns 5,602,684 shares of the company's stock worth $28,294,000 after acquiring an additional 543,995 shares in the last quarter. Geode Capital Management LLC increased its holdings in Humacyte by 4.7% in the fourth quarter. Geode Capital Management LLC now owns 2,135,133 shares of the company's stock valued at $10,785,000 after buying an additional 94,915 shares during the last quarter. CenterBook Partners LP bought a new stake in Humacyte in the fourth quarter valued at about $6,463,000. Charles Schwab Investment Management Inc. increased its holdings in Humacyte by 7.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 775,718 shares of the company's stock valued at $3,917,000 after buying an additional 54,400 shares during the last quarter. Finally, Private Advisor Group LLC increased its holdings in Humacyte by 60.7% in the fourth quarter. Private Advisor Group LLC now owns 599,700 shares of the company's stock valued at $3,028,000 after buying an additional 226,590 shares during the last quarter. Institutional investors and hedge funds own 44.71% of the company's stock.

Insider Buying and Selling

In other Humacyte news, CFO Dale A. Sander acquired 20,000 shares of the firm's stock in a transaction that occurred on Thursday, April 10th. The stock was acquired at an average cost of $1.53 per share, with a total value of $30,600.00. Following the acquisition, the chief financial officer now directly owns 40,600 shares of the company's stock, valued at $62,118. This represents a 97.09 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Kathleen Sebelius acquired 50,000 shares of the firm's stock in a transaction that occurred on Tuesday, April 8th. The stock was acquired at an average cost of $1.32 per share, with a total value of $66,000.00. Following the completion of the acquisition, the director now directly owns 91,207 shares in the company, valued at approximately $120,393.24. This represents a 121.34 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired 83,993 shares of company stock valued at $118,224 in the last three months. 11.20% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several analysts recently weighed in on HUMA shares. Benchmark reissued a "buy" rating on shares of Humacyte in a report on Thursday, February 27th. HC Wainwright reissued a "buy" rating and issued a $15.00 price objective on shares of Humacyte in a report on Wednesday, March 12th. Finally, D. Boral Capital reissued a "buy" rating and issued a $25.00 price objective on shares of Humacyte in a report on Wednesday, March 26th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $13.71.

Humacyte Stock Up 1.4 %

Shares of NASDAQ:HUMA traded up $0.02 during trading on Wednesday, hitting $1.45. 1,408,173 shares of the company traded hands, compared to its average volume of 3,584,791. The stock has a market capitalization of $224.92 million, a price-to-earnings ratio of -1.08 and a beta of 1.62. The business's fifty day moving average is $2.23 and its 200-day moving average is $3.82. Humacyte, Inc. has a one year low of $1.15 and a one year high of $9.97.

Humacyte (NASDAQ:HUMA - Get Free Report) last posted its earnings results on Friday, March 28th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.07. The company had revenue of $7.23 million for the quarter, compared to the consensus estimate of $0.64 million. On average, analysts forecast that Humacyte, Inc. will post -1.27 EPS for the current year.

Humacyte Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.